Previous 10 | Next 10 |
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 105 weeks of public selections as part of this ongoing live forward-testing. In...
SAN DIEGO , May 15, 2019 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the publication of data abstracts related to two of MEI Pharma's clinical stage drug development programs to be...
MEI Pharma (NASDAQ: MEIP ): Q3 GAAP EPS of -$0.24. More news on: MEI Pharma, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SAN DIEGO , May 9, 2019 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its third quarter ended March 31, 2019 . "As progress continues across our pipeline of four clinic...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 102 weeks of public selections as part of this ongoing live forward-testing. In...
SAN DIEGO , April 2, 2019 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Daniel P. Gold , Ph.D., president and chief executive officer, will present at the 18 th Annual Needham...
SAN DIEGO , March 12, 2019 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Daniel P. Gold , Ph.D., president and chief executive officer, will present at the 29 th Oppenheimer H...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on winning breakout selections over more than 5 years including 94 weeks of public weekly selections as part of this ongoing live forward-testing. Breakout Stock Portfolio 2019 results YTD All time total...
OncoCyte (NYSEMKT: OCX ) initiated with Buy rating and $6 (56% upside) price target at Piper Jaffray. Shares up 7% premarket. More news on: OncoCyte Corporation, Clovis Oncology, Galectin Therapeutics, Inc., Healthcare stocks news, , Stocks on the move, Read more ...
MEI Pharma (NASDAQ: MEIP ): Q2 GAAP EPS of -$0.15 misses by $0.01 . More news on: MEI Pharma, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Company Commences a Cash Preservation Plan Including a Reduction in Force MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today announced that its Board of Directors has determined unanimously to begin evaluation of the Company’s strategic alternatives, including ...
-- Ongoing Phase 1 Study Evaluating Voruciclib Plus Venetoclax Demonstrates Anti-leukemic Activity, Including Complete Responses, Anticipated Decreases in Mcl-1 and No Overlapping Toxicity in Heavily Pretreated R/R AML Patients -- -- Board of Directors Unanimously Aligned on Prioritizatio...